News

  1. ImmusanT Initiates Clinical Trials Of Nexvax2 Therapeutic Vaccine For Celiac Disease 9/4/2012

    ImmusanT announced recently that it has initiated clinical trials in New Zealand, Australia and the U.S. to evaluate Nexvax2, the first therapeutic vaccine for patients with celiac disease.

  2. Lilly Stops Phase III Development Of Pomaglumetad Methionil For The Treatment Of Schizophrenia Based On Efficacy Results 8/29/2012

    Eli Lilly and Company (NYSE: LLY) announced today the decision to stop ongoing clinical studies investigating pomaglumetad methionil, also known as mGlu2/3, for the treatment of patients suffering from schizophrenia. 

  3. LGC Is Using Nanoparticle Tracking Analysis To Characterize Novel Nanoscale Reference Materials 8/28/2012

    NanoSight, leading manufacturers of unique nanoparticle characterization technology, reports on the work of Principal Scientist Dr Damian Marshall and his colleagues at LGC as they develop new methods for characterizing new nanoscale reference materials.

  4. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis 8/23/2012

    Janssen Biologics (Ireland) announced today it has initiated the Phase 3 development program for sirukumab (CNTO 136) as part of a collaboration with GlaxoSmithKline plc (GSK).

  5. As Tuberculosis Grows More Difficult To Control, Vaccine Candidate To Prevent Disease Enters Clinical Testing 8/22/2012

     Aeras and the Infectious Disease Research Institute (IDRI) announce today the start of the first clinical trial of IDRI's novel tuberculosis vaccine candidate, ID93 + GLA-SE. The Phase I clinical trial will assess the safety, tolerability and immunogenicity of the vaccine candidate in 60 healthy adult volunteers. The study will be conducted by Johnson County Clin-Trials in Lenexa, Kansas, in close collaboration with Aeras and IDRI.

  6. AbGenomics International Obtains FDA Agreement On Its Phase 2 Clinical Trial Plans 8/17/2012

    Los Altos, CA /PRNewswire-iReach/ - AbGenomics International announced today that it has obtained agreement from U.S. Food and Drug Administration (FDA) for its proposed plans for a phase 2 clinical trial of the novel autoimmune therapeutic candidate, AbGn-168H.

  7. Teva To Initiate Third Phase III Trial Of Oral Laquinimod For The Treatment Of Relapsing Remitting Multiple Sclerosis 8/8/2012

    Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) provided today an update on the clinical development program of once-daily oral laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS).

  8. TiGenix Completes Patient Enrollment In Phase IIa Rheumatoid Arthritis Study 8/8/2012

    TiGenix (EURONEXT BRUSSELS: TIG), the European leader in cell therapy, announced today the completion of patient enrollment in the Company's Phase IIa study of Cx611, a suspension of expanded allogeneic adult stem cells, in rheumatoid arthritis.

  9. Pluristem's PLX Cells Show Efficacy In Treating Lung Disease 7/31/2012

    Pluristem Therapeutics, Inc. (NASDAQ:PSTI; TASE: PLTR), a leading developer of placenta-based cell therapies, recently announced the results of new preclinical tests that show its PLacental eXpanded (PLX) cells may be effective in reducing pulmonary fibrosis and improving lung function in a group of diseases collectively called interstitial lung disease (ILD). ILD includes the pulmonary insults occurring in the lung following its exposure to drugs, radiation or toxic chemicals and the pulmonary complications of systemic autoimmune diseases. 

  10. Merck Signs Two Deals For Novel HIV Drug Candidates And Initiates Phase II Clinical Trial Of MK-1439 For HIV 7/24/2012

    Merck, known as MSD outside the United States and Canada, announced recently that the company has signed two licensing agreements for investigational HIV drug candidates.